Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

Cellectar Biosciences Inc. (NASDAQ:CLRB) reported additional data from the first cohort of a Phase I trial in about 33 patients with relapsed or

Read the full 230 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE